WW International (WW), more commonly known as Weight Watchers, is fully embracing the popularity of GLP-1s and their impact on weight loss management with a new platform that integrates GLP-1 medications with the Weight Watchers program of nutrition management and behavioral support.
The Weight Watchers Med+ and new GLP-1 Success Program is the company’s dedicated GLP-1 medical program to provide its members with physicians and a care team who specialize in obesity and metabolic health. The team not only prescribe and dose appropriate weight loss medications but help members manage side effects, mitigate muscle loss, and provide nutritional guidance.
For individuals who receive GLP-1 prescriptions from an alternative medical provider, Weight Watchers also offers the GLP-1 Success Program as a standalone option.
In addition to the GLP-1 Success and Med+ programs, the company is also launching “Weight Watchers Score” that turns daily habits into a scoring system, and “AI Body Scanner” that tracks changes in fat and muscle mass. Both will be available globally beginning December 26.
“By integrating medical care with tools like the Weight Health Score and our AI body scanner, we can help members understand their progress more accurately to improve their metabolic health and sustain results long-term,” said Weight Watchers’ Chief Medical Officer Dr. Kim Boyd.
The new platform and integration of weight loss management drugs led the company to adopt a new brand identity and bring back its old name – Weight Watchers — with an updated logo.
By tapping into the proliferation and popularity of weight loss drugs like Ozempic (NVO), Wegovy (NVO), and Mounjaro (LLY) with support programs, Weight Watchers (WW) hopes to maintain relevancy in a new landscape of weight management.
“We recognized early that this was not the end of an era, but the beginning of a new one. The future of weight management will be built on an integrated approach that pairs clinical care and medication access with structured nutrition, movement and accountability,” CEO Tara Comonte said on the company’s most recent earnings call with analysts, announcing at that time the Weight Watchers’ app and website were undergoing a full digital transformation “to remove legacy barriers between our clinical and behavioral offerings.”
Accordingly, shares are higher on Tuesday, helping to trim the stock’s 8% YTD loss.